Do glucagon-like peptide‑1 receptor agonists (e.g., exenatide, liraglutide, dulaglutide, semaglutide) interact with the levonorgestrel‑releasing intrauterine device (Mirena)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No Clinically Significant Interaction Between GLP-1 Receptor Agonists and Mirena IUD

GLP-1 receptor agonists do not interact with the levonorgestrel-releasing intrauterine device (Mirena IUD) and can be used safely together without compromising contraceptive efficacy.

Key Evidence

The Mirena IUD delivers levonorgestrel locally to the uterus, bypassing first-pass metabolism and oral absorption pathways entirely. This fundamental difference in drug delivery eliminates the theoretical concern about GLP-1 RA-induced delayed gastric emptying affecting contraceptive absorption—a concern that only applies to oral contraceptives 1, 2.

Direct Pharmacokinetic Studies

High-quality drug interaction studies demonstrate that:

  • Semaglutide (oral formulation) does not reduce the bioavailability of levonorgestrel when given as an oral contraceptive. The AUC ratio was 1.06 (90% CI: 0.97-1.17), well within the no-effect criterion of 0.80-1.25 1

  • A separate study confirmed semaglutide did not reduce levonorgestrel bioavailability, though it showed a 20% increase in levonorgestrel AUC (1.20 [1.15-1.26])—an increase that is not clinically concerning and does not reduce contraceptive efficacy 2

  • The Cmax (peak concentration) of levonorgestrel remained unaffected by GLP-1 RA co-administration 1, 2

Why the Mirena IUD Is Even Safer

While these studies examined oral levonorgestrel, the Mirena IUD provides an even more favorable scenario because:

  1. Local delivery: Levonorgestrel is released directly into the uterine cavity, achieving high local concentrations with minimal systemic absorption
  2. No gastric involvement: The IUD completely bypasses the gastrointestinal tract, making GLP-1 RA effects on gastric emptying irrelevant
  3. Steady-state release: The IUD provides continuous hormone release independent of any oral drug absorption dynamics

Clinical Implications

You can confidently prescribe GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide) to patients using Mirena IUDs without any special precautions or concerns about contraceptive failure.

Important Context from Recent Literature

Recent evidence suggests that combining GLP-1 RAs with levonorgestrel-releasing IUDs may actually be preferred in obese women because oral progestin bioavailability is reduced in obesity, whereas IUD delivery maintains efficacy 3. This combination has been associated with reduced endometrial cancer risk in high-risk women 3.

Common Pitfall to Avoid

Do not confuse this situation with oral contraceptives. While GLP-1 RAs may theoretically affect oral contraceptive absorption due to delayed gastric emptying 4, this concern does not apply to IUDs, implants, patches, or injections—all of which bypass the GI tract entirely.

Bottom Line

The Mirena IUD and GLP-1 receptor agonists have no pharmacokinetic or pharmacodynamic interaction. Contraceptive efficacy remains fully intact, and no additional contraceptive precautions are needed when starting or continuing GLP-1 RA therapy in patients with Mirena IUDs.

Related Questions

Do GLP‑1 receptor agonists (e.g., exenatide, liraglutide, dulaglutide, semaglutide) reduce the effectiveness of combined oral contraceptives?
Do any of the following medications (trazodone, methocarbamol, gabapentin, pregabalin, duloxetine, magnesium oxide, hydroxyzine, tramadol, losartan‑hydrochlorothiazide, amlodipine [Toprol XL], montelukast, and hyzaar [losartan‑hydrochlorothiazide]) interact with GLP‑1 receptor agonists?
What are the current guidelines for managing GLP‑1 receptor agonist therapy in a patient of reproductive age who is planning pregnancy?
Can GLP‑1 receptor agonists (e.g., liraglutide, semaglutide, exenatide) cause changes in the menstrual cycle of a perimenopausal woman (approximately 45–55 years old)?
Are there any interactions between GLP-1 (Glucagon-like peptide-1) receptor agonists, SSRIs (Selective Serotonin Reuptake Inhibitors), and ADHD (Attention Deficit Hyperactivity Disorder) medications?
What are the guidelines for screening patients for bipolar disorder?
Should a new right bundle branch block (RBBB) and left bifascicular block be investigated in an otherwise asymptomatic patient?
In a 5-year-old who developed gait disturbance, loss of speech, and a right-hand resting tremor after a febrile rash illness but has no history of encephalopathy, is subacute sclerosing panencephalitis still a likely diagnosis?
Is Tri‑Lo‑Marzia (ethinyl estradiol/norgestimate) safe for a woman with risk factors for venous thromboembolism, and what is her risk of pulmonary embolism?
Is washing underwear at 60 °C for 90 minutes sufficient to inactivate mold spores and Escherichia coli on washable fabrics?
How is ureaplasma urealyticum infection diagnosed and treated, including recommendations for pregnant patients?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.